Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Accumulated Expenses: 2020-2024

Historic Other Accumulated Expenses for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $1,000.

  • Foghorn Therapeutics' Other Accumulated Expenses rose 85.92% to $396,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $396,000, marking a year-over-year increase of 85.92%. This contributed to the annual value of $1,000 for FY2024, which is 97.22% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Other Accumulated Expenses of $1,000 as of FY2024, which was down 97.22% from $36,000 recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Other Accumulated Expenses ranged from a high of $392,000 in FY2021 and a low of $1,000 during FY2024.
  • Its 3-year average for Other Accumulated Expenses is $118,333, with a median of $36,000 in 2023.
  • As far as peak fluctuations go, Foghorn Therapeutics' Other Accumulated Expenses spiked by 184.06% in 2021, and later tumbled by 97.22% in 2024.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Other Accumulated Expenses stood at $138,000 in 2020, then spiked by 184.06% to $392,000 in 2021, then fell by 18.88% to $318,000 in 2022, then plummeted by 88.68% to $36,000 in 2023, then crashed by 97.22% to $1,000 in 2024.